HbA1c Variability in Type II Diabetes

NAActive, not recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

October 1, 2023

Study Completion Date

October 1, 2026

Conditions
Diabetes Mellitus Type 2
Interventions
DRUG

Metformin

Initial: 500 mg once daily; dosage may be increased by 500 mg weekly; maximum dose: 2,000 mg once daily

DRUG

Gliclazide

"There is no fixed-dosage regimen for the management of diabetes mellitus with gliclazide. Dose will be individualized based on frequent determinations of blood glucose during dose titration and throughout maintenance. The 30 mg modified-release tablet equals the 80 mg immediate-release tablet.~Immediate-release tablet: Initial: 80 mg twice daily; titrate based on blood glucose levels. Usual dosage range: 80 to 320 mg/day (maximum dose: 320 mg/day); dosage of ≥160 mg should be divided into 2 equal parts for twice-daily administration.~Modified-release tablet: Initial: 30 mg once daily; titrate in 30 mg increments every 2 weeks based on blood glucose levels. Maximum dose: 120 mg once daily"

DRUG

Sitagliptin

Oral: 100 mg once daily

DRUG

Liraglutide

SubQ: Initial: 0.6 mg once daily for 1 week; then increase to 1.2 mg once daily; may increase further to 1.8 mg once daily if optimal glycemic response not achieved with 1.2 mg daily.

DRUG

Pioglitazone

"Oral, Monotherapy or combination therapy: 15-30 mg once daily~Patients with heart failure (NYHA Class I or II): Monotherapy or combination therapy: 15 mg once daily"

DRUG

Dapagliflozin

5mg once daily increasing to 10mg once daily as required

DRUG

human insulin

insulin dosage and administration according to physician

Trial Locations (1)

3050

Hamad Medical Corporation, Doha

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Hamad Medical Corporation

INDUSTRY

collaborator

Sidra Medicine

OTHER

collaborator

University of Hull

OTHER

lead

Weill Cornell Medical College in Qatar

OTHER

NCT02879409 - HbA1c Variability in Type II Diabetes | Biotech Hunter | Biotech Hunter